AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Biotage

Legal Proceedings Report Aug 16, 2017

2894_rns_2017-08-16_295445ab-0c2c-4ce3-8532-f22474847d5a.pdf

Legal Proceedings Report

Open in Viewer

Opens in native device viewer

Press release Biotage AB

Contact persons: SE-751 03 Uppsala Torben Jörgensen, CEO Tel:018 56 59 00 Tel: 0707-49 05 84, [email protected] www.biotage.com

Box 8

Uppsala August 16, 2017

Biotage – alleged patent infringement settled - correction

In the press release with the heading "Biotage – alleged patent infringement settled" published earlier today, reference was by mistake made to the EU Market Abuse Regulation and the Securities Markets Act in the label of the press release. Since the information was not regarded as insider information the reference should not have been included.

This information was submitted for publication, through the agency of the contact persons set out above, at 11.00 CET on August 16, 2017.

About Biotage

Biotage offers efficient separation technologies from analysis to industrial scale and high quality solutions for analytical chemistry from research to commercial analysis laboratories. Biotage's products are used by government authorities, academic institutions, pharmaceutical and food companies, among others. The company is headquartered in Uppsala and has offices in the US, UK, China, Japan and South Korea. Biotage has approx. 330 employees and had sales of 667 MSEK in 2016. Biotage is listed on the NASDAQ OMX Nordic. Website: www.biotage.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.